Paul Josephs - Lifecore Biomedical CEO President
| LFCR Stock | 6.58 0.07 1.05% |
CEO
Paul Josephs is CEO President of Lifecore Biomedical
| Age | 59 |
| Address | 3515 Lyman Boulevard, Chaska, MN, United States, 55318 |
| Phone | (952) 368-4300 |
| Web | https://www.lifecore.com |
Latest Insider Transactions
Paul Josephs Latest Insider Activity
Tracking and analyzing the buying and selling activities of Paul Josephs against Lifecore Biomedical stock is an integral part of due diligence when investing in Lifecore Biomedical. Paul Josephs insider activity provides valuable insight into whether Lifecore Biomedical is net buyers or sellers over its current business cycle. Note, Lifecore Biomedical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Lifecore Biomedical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Paul Josephs over a week ago Disposition of 8975 shares by Paul Josephs of Lifecore Biomedical subject to Rule 16b-3 | ||
Paul Josephs over two months ago Acquisition by Paul Josephs of 17000 shares of Lifecore Biomedical at 5.74 subject to Rule 16b-3 |
Lifecore Biomedical Management Efficiency
The company has return on total asset (ROA) of (0.0247) % which means that it has lost $0.0247 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2958) %, meaning that it created substantial loss on money invested by shareholders. Lifecore Biomedical's management efficiency ratios could be used to measure how well Lifecore Biomedical manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/21/2025, Return On Tangible Assets is likely to drop to -0.02. In addition to that, Return On Capital Employed is likely to drop to 0.01. At this time, Lifecore Biomedical's Non Currrent Assets Other are relatively stable compared to the past year. As of 03/21/2025, Other Assets is likely to grow to about 25.1 M, while Total Assets are likely to drop slightly above 248.7 M.Similar Executives
| Found 2 records | CEO Age | ||
| Anatoly MD | Shuttle Pharmaceuticals | 81 | |
| Irwin Simon | Tilray Inc | 67 | |
Management Performance
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.0247 |
Lifecore Biomedical Leadership Team
Elected by the shareholders, the Lifecore Biomedical's board of directors comprises two types of representatives: Lifecore Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lifecore. The board's role is to monitor Lifecore Biomedical's management team and ensure that shareholders' interests are well served. Lifecore Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lifecore Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Darren Hieber, Senior Partnerships | ||
| Parker Javid, Vice President | ||
| Matt Augustson, Senior Technology | ||
| Aaron Perlitsh, Director Officer | ||
| Thomas Guldager, Senior Operations | ||
| James Hall, President CEO | ||
| Kara Morley, Senior Resources | ||
| Brikkelle Thompson, Senior Resources | ||
| John Morberg, Executive CFO | ||
| Paul Josephs, CEO President | ||
| Steve Laninga, Vice Operations | ||
| Jackie Klecker, Executive Services | ||
| Kipling Thacker, VP Scientist | ||
| Ryan CPA, CFO Secretary | ||
| Albert Bolles, I Foods |
Lifecore Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lifecore Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.0247 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | (0.05) % | ||||
| Current Valuation | 365.14 M | ||||
| Shares Outstanding | 37.03 M | ||||
| Shares Owned By Insiders | 4.52 % | ||||
| Shares Owned By Institutions | 73.59 % | ||||
| Number Of Shares Shorted | 2.4 M | ||||
| Price To Book | 15.75 X |
Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.